Breast Neoplasms — Expanded Access Programs
Overview
Right2Hope maintains a directory of 32 expanded access programs, clinical trials, and compassionate use pathways listed for Breast Neoplasms. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with breast neoplasms programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 20 programs are currently active or recruiting, with the remaining 12 in other lifecycle stages. Sponsors actively running programs in this area include Merck Sharp & Dohme LLC, Eli Lilly and Company, Pfizer, Washington University School of Medicine, Actuate Therapeutics Inc., and others.
By recruiting status
Snapshot of where every Breast Neoplasms program currently sits in its lifecycle.
- Active / Recruiting20
- Inactive12
Top sponsors
Organisations running the most Breast Neoplasms programs in the directory.
- Merck Sharp & Dohme LLC6 programs
- Eli Lilly and Company4 programs
- Pfizer2 programs
- Washington University School of Medicine2 programs
- Actuate Therapeutics Inc.1 program
- Alliance for Clinical Trials in Oncology1 program
- AstraZeneca1 program
- Atossa Therapeutics, Inc.1 program
- BicycleTx Limited1 program
- BioNTech SE1 program
Breast Neoplasms programs (32)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on 9-ING-41 for Patients with Advanced Cancers — Actuate Therapeutics Inc.
- Study on Patritumab Deruxtecan for Treating Breast Cancer (MK-1022-016) — Merck Sharp & Dohme LLC
- Study on Sacituzumab Tirumotecan (Sac-TMT, MK-2870) for Treating Breast Cancer — Merck Sharp & Dohme LLC
- Long-term Study for Continued Niraparib Treatment in Participants from Previous Studies — GlaxoSmithKline
- Study on Abemaciclib and Fulvestrant for Women with Hormone Receptor Positive, HER2 Negative Breast Cancer — Eli Lilly and Company
- Study on Disitamab Vedotin for Adults with Advanced HER2 Positive Breast Cancer — Pfizer
- Study of Imlunestrant in Premenopausal Women with ER+ HER2- Early Breast Cancer — Eli Lilly and Company
- Study Comparing Izalontamab Brengitecan to Chemotherapy for Advanced or Metastatic Triple-negative Breast Cancer — Bristol-Myers Squibb
- Study on LY4064809 with Other Cancer Treatments for Advanced Breast Cancer with a PIK3CA Genetic Change — Eli Lilly and Company
- Study on Adjusting Fluoropyrimidine (FP) Doses Based on DPYD Gene Testing — Rutgers, The State University of New Jersey
- Study on PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer — Washington University School of Medicine
- Study on Pembrolizumab, IRX-2, and Chemotherapy for Triple Negative Breast Cancer — Providence Health & Services
- Phase II Study Comparing Capecitabine and Elacestrant with Capecitabine Alone in ER+ Breast Cancer (CAPELA) — Kristina A. Fanucci
- Study on the Effects and Safety of Pumitamig for Patients with Triple-Negative Breast Cancer — BioNTech SE
- Study on Patritumab Deruxtecan and Pembrolizumab with Other Cancer Drugs for High-Risk Early-Stage Breast Cancer — Merck Sharp & Dohme LLC
- Study of Patritumab Deruxtecan with Other Cancer Drugs for HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed — Merck Sharp & Dohme LLC
- Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for Certain Types of Advanced Breast Cancer — Merck Sharp & Dohme LLC
- Study on the Tolerability of Lapatinib and Trastuzumab in Adults Aged 60 or Older with HER2 Positive Advanced Breast Cancer — City of Hope Medical Center
- Study on Trastuzumab Deruxtecan (T-DXd) Alone or with THP Compared to Standard Treatment for HER2-positive Early Breast Cancer — AstraZeneca
- Study on Ibrutinib and Trastuzumab for HER2-Positive Metastatic Breast Cancer — US Oncology Research
- Study on (Z)-Endoxifen for Treating Premenopausal Women with ER+/HER2- Breast Cancer — Atossa Therapeutics, Inc.
- Study on Disitamab Vedotin Alone or With Other Cancer Drugs for Solid Tumors — Seagen Inc.
- Study Comparing Imlunestrant to Standard Hormone Therapy in Patients with Early Breast Cancer — Eli Lilly and Company
- Study on Sacituzumab Tirumotecan Alone and with Pembrolizumab Compared to Doctor's Choice Treatment for Advanced HR+/HER2- Breast Cancer — Merck Sharp & Dohme LLC
- Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score — Washington University School of Medicine
- I-SPY Trial: New and Personalized Treatments for Breast Cancer Before Surgery — QuantumLeap Healthcare Collaborative
- Study on Leflunomide for Previously Treated Metastatic Triple Negative Breast Cancer — Joseph Sparano
- Study on Durvalumab with Olaparib and/or Cediranib for Advanced Cancers, Including Ovarian, Breast, Lung, Prostate, and Colorectal — National Cancer Institute (NCI)
- Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies — BicycleTx Limited
- Study of Abemaciclib and Elacestrant for Patients with Brain Metastasis from ER+/HER-2- Breast Cancer — Stemline Therapeutics, Inc.
- Study to Test the Safety and Tolerability of PF-07220060 in Participants with Advanced Solid Tumors — Pfizer
- Study on the Effect of Denosumab in Preventing Breast Cancer in Women with a BRCA1 Gene Mutation — Alliance for Clinical Trials in Oncology
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Breast Neoplasms to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.